Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer

2013 ◽  
Vol 130 (3) ◽  
pp. 511-517 ◽  
Author(s):  
Suzanne Leijen ◽  
Stephan A. Veltkamp ◽  
Alwin D.R. Huitema ◽  
E. van Werkhoven ◽  
Jos H. Beijnen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Population Pharmacokinetic Analysis ◽  
Fixed Dose ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic ◽  
Second Line ◽  
Second Line Therapy ◽  
Dose Escalation Study ◽  
Line Therapy ◽  
Fixed Dose Rate

scholarly journals The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good

2010 ◽  
Vol 4 (1) ◽  
pp. 37-40 ◽  
Author(s):  
Jorge Bermudez ◽  
Ellen 't Hoen
Keyword(s):  
Common Good ◽  
Quality Standards ◽  
Fixed Dose ◽  
Pharmaceutical Companies ◽  
Second Line ◽  
First Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Patent Pool ◽  
The Common

Developing and delivering appropriate, affordable, well-adapted medicines for HIV/AIDS remains an urgent challenge: as first-line therapies fail, increasing numbers of people require costly second-line therapy; one-third of ARVs are not available in pediatric formulations; and certain key first- and second-line triple fixed-dose combinations do not exist or sufficient suppliers are lacking. UNITAID aims to help solve these problems through an innovative initiative for the collective management of intellectual property (IP) rights – a patent pool for HIV medicines. The idea behind a patent pool is that patent holders - companies, governments, researchers or universities - voluntarily offer, under certain conditions, the IP related to their inventions to the patent pool. Any company that wants to use the IP to produce or develop medicines can seek a license from the pool against the payment of royalties, and may then produce the medicines for use in developing countries (conditional upon meeting agreed quality standards). The patent pool will be a voluntary mechanism, meaning its success will largely depend on the willingness of pharmaceutical companies to participate and commit their IP to the pool. Generic producers must also be willing to cooperate. The pool has the potential to provide benefits to all.

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

1992 ◽  
Vol 47 (3) ◽  
pp. 282-286 ◽  
Author(s):  
Ignace Vergote ◽  
Anna Himmelmann ◽  
Bo Frankendal ◽  
Marit Scheistrøen ◽  
Kerstin Vlachos ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

1999 ◽  
Vol 72 (1) ◽  
pp. 60-64 ◽  
Author(s):  
Giorgio Bolis ◽  
Fabio Parazzini ◽  
Giovanna Scarfone ◽  
Antonella Villa ◽  
Mariangela Amoroso ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Platinum Refractory
Sign in / Sign up

Export Citation Format

Share Document